|
Parameters
|
plakoglobin
|
p value
|
E-cadherin
|
p value
|
|---|
|
High (n = 21)
|
Low (n = 100)
|
High (n = 71)
|
Low (n = 50)
|
|---|
|
HR and HER2 status
| |
|
TNBC
|
4 (19.0%)
|
35 (35.0%)
|
0.203
|
15 (21.1%)
|
24 (48.0%)
|
0.003
|
|
non-TNBC
|
17 (81.0%)
|
65 (65.0%)
|
56 (78.9%)
|
26 (52.0%)
|
|
HER2 status
|
|
negative
|
16 (76.2%)
|
70 (70.0%)
| |
47 (66.2%)
|
39 (78.0%)
|
0.222
|
|
positive
|
5 (23.8%)
|
30 (30.0%)
|
0.792
|
24 (33.8%)
|
11 (22.0%)
|
|
Age at operation
|
|
≤ 56
|
12 (57.1%)
|
45 (45.0%)
|
0.344
|
34 (47.9%)
|
23 (46.0%)
|
0.855
|
|
> 56
|
9 (42.9%)
|
55 (55.0%)
|
37 (52.1%)
|
27 (54.0%)
|
|
Menopause
|
|
Negative
|
10 (47.6%)
|
38 (38.0%)
|
0.466
|
28 (39.4%)
|
20 (40.0%)
|
0.950
|
|
Positive
|
11 (52.4%)
|
62 (62.0%)
|
43 (60.6%)
|
30 (60.0%)
|
|
Tumor size
|
|
≤ 2 cm
|
2 (9.5%)
|
15 (15.0%)
|
0.734
|
9 (12.7%)
|
8 (16.0%)
|
0.607
|
|
> 2 cm
|
19 (90.5%)
|
85 (85.0%)
|
62 (87.3%)
|
42 (84.0%)
|
|
Lymph node status
|
|
Negative
|
8 (38.1%)
|
27 (27.0%)
|
0.304
|
23 (32.4%)
|
12 (24.0%)
|
0.416
|
|
Positive
|
13 (61.9%)
|
73 (73.0%)
|
48 (67.6%)
|
38 (76.0%)
|
|
Nuclear grade
|
|
1, 2
|
16 (76.2%)
|
78 (78.0%)
|
0.857
|
54 (76.1%)
|
40 (80.0%)
|
0.663
|
|
3
|
5 (23.8%)
|
22 (22.0%)
|
17 (23.9%)
|
10 (20.0%)
|
|
Ki67
|
|
≤ 14%
|
6 (28.6%)
|
45 (45.0%)
|
0.225
|
30 (42.3%)
|
21 (42.0%)
|
0.978
|
|
> 14%
|
15 (71.4%)
|
55 (55.0%)
|
41 (57.7%)
|
29 (58.0%)
|
|
Pathological response
|
|
pCR
|
7 (33.3%)
|
41 (41.0%)
|
0.627
|
39 (54.9%)
|
34 (68.0%)
|
0.187
|
|
non-pCR
|
14 (66.7%)
|
59 (59.0%)
|
32 (45.1%)
|
16 (32.0%)
|
|
Plakoglobin
|
|
Low
|
Not
|
Not
| |
54 (76.1%)
|
46 (92.0%)
|
0.023
|
|
High
|
determined
|
determined
|
17 (23.9%)
|
4 (8.0%)
|
|
E-cadherin
|
|
Negative
|
4 (19.0%)
|
46 (46.0%)
|
0.023
|
Not
|
Not
| |
|
Positive
|
17 (81.0%)
|
54 (54.0%)
|
determined
|
determined
|
-
HER2 human epidermal growth factor receptor 2; HR hormone receptor; pCR pathological complete response; TNBC triple-negative breast cancer
